Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis

References

• ChunJHartungHPMechanism of action of oral fingolimod (FTY720) in multiple sclerosisClin Neuropharmacol2010332 91 10120061941
   PubMed Web of Science ®Google Scholar
• CherwinskiHMCohnRGCheungPThe immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesisJ Pharmacol Exp Ther19952752 1043 10497473131
   PubMed Web of Science ®Google Scholar
• RuckemannKFairbanksLDCarreyEALeflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humansJ Biol Chem199827334 21682 216919705303
   PubMed Web of Science ®Google Scholar
• Bar-OrAPachnerAMenguy-VacheronFKaplanJWiendlHTeriflunomide and its mechanism of action in multiple sclerosisDrugs2014746 659 67424740824
   PubMed Web of Science ®Google Scholar
• SingerBComiGMillerAFrequency of infections during treatment with teriflunomide: pooled data from three placebo-controlled teriflunomide studiesNeurology2013807 Supplement P01.171
   Google Scholar
• ScannevinRHChollateSJungMYFumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathwayJ Pharmacol Exp Ther20123411 274 28422267202
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA)Allegato I. Riassunto delle carattersitiche del prodotto [Fingolimod summary of product characteristics] Available from: http://www.ema.europa.eu/docs/it_IT/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdfAccessed July 14, 2017 Italian
   Google Scholar
• US FDAGILENYA (fingolimod); highlights of prescribing information Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022527s008lbl.pdfAccessed July 14, 2017
   Google Scholar
• European Medicines Agency (EMA)Teriflunomide Summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002514/WC500148682.pdfAccessed July 14, 2017
   Google Scholar
• US FDAAUBAGIO (teriflunomide); highlights of prescribing information Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202992s000lbl.pdfAccessed July 14, 2017
   Google Scholar
• European Medicines Agency (EMA)Dimethyl fumarate; summary of product characteristics Available from: http://www.ema.europa.eu/docs/it_IT/document_library/EPAR_-_Product_Information/human/002601/WC500162069.pdfAccessed July 14, 2017
   Google Scholar
• US FDATECFIDERA™ (dimethyl fumarate); highlights of prescribing information Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204063lbl.pdfAccessed July 14, 2017
   Google Scholar
• KapposLRadueEWO’ConnorPFREEDOMS Study GroupA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisNew Engl J Med20103625 387 40120089952
   PubMed Web of Science ®Google Scholar
• KapposLAntelJComiGFTY720 D2201 Study GroupOral fingolimod (FTY720) for relapsing multiple sclerosisN Engl J Med200635511 1124 114016971719
   PubMed Web of Science ®Google Scholar
• ComiGO’ConnorPMontalbanXFTY720D2201 Study GroupPhase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year resultsMult Scler2010162 197 20720028707
   PubMed Web of Science ®Google Scholar
• IzquierdoGO’ConnorPMontalbanXFive-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosisMult Scler J2014207 877 881
   Web of Science ®Google Scholar
• KapposLRadueEWO’ConnorPFingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis: results from a phase 3, placebo-controlled study (FREEDOMS)Neurology201176Suppl 4 A563
   Google Scholar
• CohenJABarkhofFComiGOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med20103625 402 41520089954
   PubMed Web of Science ®Google Scholar
• KhatriBBarkhofFComiGJinJFrancisGCohenJFingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN-b1a: results from a Phase 3, active-controlled study (TRANSFORMS)Neurology2012781 Supplement PD5.006
   Google Scholar
• CalabresiPARadueE-WGoodinDSafety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialLancet Neurol2014136 545 55624685276
   PubMed Web of Science ®Google Scholar
• KapposLO’ConnorPRadueEWLong-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trialNeurology20158415 1582 159125795646
   PubMed Web of Science ®Google Scholar
• CohenJAKhatriBBarkhofFTRANSFORMS (TRial Assessing injectable interferoN vS.FTY720 Oral in RRMS) Study GroupLong-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS studyJ Neurol Neurosurg Psychiatry2016875 468 47526111826
   PubMed Web of Science ®Google Scholar
• KapposLDe StefanoNFreedmanMSInclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosisMult Scler20162210 1297 130526585439
   PubMed Web of Science ®Google Scholar
• NovartisNovartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS Available from: https://novartis.gcs-web.com/static-files/435c32df-e6ed-434d-9a78-3178e9912b8dAccessed July 14, 2017
   Google Scholar
• NixonRBergvallNTomicDSfikasNCutterGGiovannoniGNo evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosisAdv Ther20143111 1134 115425414048
   PubMed Web of Science ®Google Scholar
• O’ConnorPWolinskyJSConfavreuxCTEMSO Trial GroupRandomized trial of oral teriflunomide for relapsing multiple sclerosisN Engl J Med201136514 1293 130321991951
   PubMed Web of Science ®Google Scholar
• FreedmanMO’ConnorPWolinskyJTeriflunomide increases the proportion of patients free from disease activity in the TEMSO Phase III studyNeurology2012781 Supplement PD5.007
   Google Scholar
• ConfavreuxCO’ConnorPComiGTOWER Trial GroupOral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Neurol2014133 247 25624461574
   PubMed Web of Science ®Google Scholar
• O’ConnorPWLublinFDWolinskyJSTeriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid useJ Neurol201326010 2472 248023852658
   PubMed Web of Science ®Google Scholar
• MillerAEWolinskyJSKapposLTOPIC Study GroupOral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Neurol20141310 977 98625192851
   PubMed Web of Science ®Google Scholar
• VermerschPCzlonkowskaAGrimaldiLMETENERE Trial GroupTeriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trialMult Scler2014206 705 71624126064
   PubMed Web of Science ®Google Scholar
• MillerAEMacdonellRComiGTeriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER studyJ Neurol20142619 1781 178824972678
   PubMed Web of Science ®Google Scholar
• GoldRKapposLArnoldDLDEFINE Study InvestigatorsPlacebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosisN Engl J Med201236712 1098 110722992073
   PubMed Web of Science ®Google Scholar
• FoxRJMillerDHPhillipsJTCONFIRM Study InvestigatorsPlacebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosisNew Engl J Med201236712 1087 109722992072
   PubMed Web of Science ®Google Scholar
• GoldRArnoldDLBar-OrALong-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension studyMult Scler2017232 253 26527207449
   PubMed Web of Science ®Google Scholar
• HavrdovaEGoldRFoxRBG-12 (dimethyl fumarate) treatment for relapsing-remitting multiple sclerosis (RRMS) increases the proportion of patients free of measured clinical and neuroradiologic disease activity in the phase 3 studiesNeurology2013807 Supplement P07.106
   Google Scholar
• HavrdovaEGiovannoniGGoldREffect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studiesEur J Neurol2017245 726 73328328179
   PubMed Web of Science ®Google Scholar
• VigliettaVMillerDBar-OrAEfficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trialsAnn Clin Transl Neurol201522 103 11825750916
   PubMed Web of Science ®Google Scholar
• HughesBCascioneMFreedmanMSEPOC study investigatorsFirst-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosisMult Scler Relat Disord201435 620 62826265274
   PubMed Web of Science ®Google Scholar
• KapposLCohenJCollinsWFingolimod in relapsing multiple sclerosis: an integrated analysis of safety findingsMult Scler Relat Dis201434 494 504
   PubMed Web of Science ®Google Scholar
• ConfavreuxCLiDKFreedmanMSTeriflunomide Multiple Sclerosis Trial GroupLong-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 yearsMult Scler2012189 1278 128922307384
   PubMed Web of Science ®Google Scholar
• ArvinAMWolinskyJSKapposLVaricella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for managementJAMA Neurol2015721 31 3925419615
   PubMed Web of Science ®Google Scholar
• US FDAFDA Drug Safety Communication: FDA warns about cases of rare brain infection with MS drug Gilenya (fingolimod) in two patients with no prior exposure to immunosuppressant drugs Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM457120.pdfAccessed July 14, 2017
   Google Scholar
• EMANew recommendations to minimise risks of the rare brain infection PML and a type of skin cancer with Gilenya Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/news_detail_002447.jsp&mid=WC0b01ac058004d5c1Accessed July 14, 2017
   Google Scholar
• KillesteinJVennegoorAvan GoldeAELBourezRLJHWijlensMLBWattjesMPPML-IRIS during Fingolimod Diagnosed after Natalizumab DiscontinuationCase Rep Neurol Med20142014 30787225506447
   PubMedGoogle Scholar
• CalicZCappelen-SmithCHodgkinsonSJMcDougallACuganesanRBrewBJTreatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumabJ Clin Neurosci2015223 598 60025523125
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyUpdated recommendations to minimise the risk of the rare brain infection PML with Tecfidera Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/10/news_detail_002423.jsp&mid=WC0b01ac058004d5c1Accessed 14 July, 2017
   Google Scholar
• RosenkranzTNovasMTerborgCPML in a patient with lymphocytopenia treated with dimethyl fumarateN Engl J Med201537215 1476 147825853765
   PubMed Web of Science ®Google Scholar
• NieuwkampDJMurkJ-Lvan OostenBWPML in Dutch MS Patients ConsortiumPML in a patient without severe lymphocytopenia receiving dimethyl fumarateN Engl J Med201537215 1474 147625853764
   PubMed Web of Science ®Google Scholar
• EMANew recommendations to minimise risks of the rare brain infection PML and a type of skin cancer with Gilenya Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/news_detail_002447.jsp&mid=WC0b01ac058004d5c1Accessed July 14, 2017
   Google Scholar
• JainNBhattiMTFingolimod-associated macular edema: incidence, detection, and managementNeurology2012789 672 68022371414
   PubMed Web of Science ®Google Scholar
• ZarbinMAJampolLMJagerRDOphthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosisOphthalmology20131207 1432 143923531349
   PubMed Web of Science ®Google Scholar
• SweetserMTDawsonKTBozicCManufacturer’s response to case reports of PMLN Engl J Med201336817 1659 166123614605
   PubMed Web of Science ®Google Scholar
• Van OostenBWKillesteinJBarkhofFPolmanCHWattjesMPPML in a patient treated with dimethyl fumarate from a compounding pharmacyN Engl J Med201336817 1658 165923614604
   PubMed Web of Science ®Google Scholar